Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on discovering and developing small-molecule therapies for virology and immunology. Its pipeline includes EDP-514, a phase 1b program for chronic hepatitis B infection; zelicapavir and EDP-323, both in phase II development for respiratory syncytial virus; EDP-235, a phase II candidate for human coronaviruses; EDP-978 for chronic spontaneous urticaria; and EPS-3903 for atopic dermatitis. The company also works on antiviral protease inhibitors, including glecaprevir, for chronic hepatitis C infection. Enanta maintains a collaborative development and license agreement with Abbott Laboratories covering HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Incorporated in 1995, Enanta is headquartered in Watertown, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ENTA
|
$12.19
|
-10.1% Downside
|
Fair
|
$21.17
|
56.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-6.3x
|
3.4x
|
5.7x
|
382.7 M
|
352.7 M
|
32.8%
|
69.0%
|
-0.7
|
—
|
15.5%
|
